Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead

2025-11-12 14:52:18 ET

Thesis

Abeona Therapeutics Inc. ( ABEO ) reported some pretty attractive figures for 3Q25, and the stock is already up 22% post announcement. GAAP EPS came in at just -$0.10, beating expectations by $0.18. The company also ended the quarter with a hefty $207.5 million in cash, cash equivalents, restricted cash, and short-term investments, which should see out a runway of over two years. This will, of course, be pivotal to help support operations and the upcoming Zevaskyn commercial launch. The one snag on earnings was that the FDA has requested a rapid sterility release assay, and Abeona needs a bit of time to optimize how they'll go about it. We should then see the Zevaskyn launch in 4Q25. I'm anticipating just a modest 5% penetration rate in 1Q26 to generate about $71.3 million in potential revenue, as I'll explain. What makes me more bullish on this figure is that CMS has already assigned a permanent J-code, which should be effective January 2026. Despite the share jump, the valuation profile still appears relatively attractive, and I don't think it is too late for investors to jump in ahead of launch. ...

Read the full article on Seeking Alpha

For further details see: